3pnw Citations

CDR-H3 diversity is not required for antigen recognition by synthetic antibodies.

J Mol Biol 425 803-11 (2013)
Cited: 103 times
EuropePMC logo PMID: 23219464

Abstract

A synthetic phage-displayed antibody repertoire was constructed with equivalent chemical diversity in the third complementarity-determining regions of the heavy (CDR-H3) and light (CDR-L3) chains, which contrasts with natural antibodies in which CDR-H3 is much more diverse than CDR-L3 due to the genetic mechanisms that generate antibody encoding genes. Surprisingly, the synthetic repertoire yielded numerous functional antibodies that contained mutated CDR-L3 sequences but a fixed CDR-H3 sequence. Alanine-scanning analysis of antibodies that recognized 10 different antigens but contained a common CDR-H3 loop showed that, in most cases, the fixed CDR-H3 sequence was able to contribute favorably to antigen recognition, but in some cases, the loop was functionally inert. Structural analysis of one such antibody in complex with antigen showed that the inert CDR-H3 loop was nonetheless highly buried at the antibody-antigen interface. Taken together, these results show that CDR-H3 diversity is not necessarily required for the generation of antibodies that recognize diverse protein antigens with high affinity and specificity, and if given the chance, CDR-L3 readily assumes the dominant role for antigen recognition. These results contrast with the commonly accepted view of antigen recognition derived from the analysis of natural antibodies, in which CDR-H3 is presumed to be dominant and CDR-L3 is presumed to play an auxiliary role. Furthermore, the results show that natural antibody function is genetically constrained, and it should be possible to develop more functional synthetic antibody libraries by expanding the diversity of CDR-L3 beyond what is observed in nature.

Articles - 3pnw mentioned but not cited (5)

  1. CDR-H3 diversity is not required for antigen recognition by synthetic antibodies. Persson H, Persson H, Ye W, Wernimont A, Adams JJ, Koide A, Koide S, Lam R, Sidhu SS. J Mol Biol 425 803-811 (2013)
  2. Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis. Remacle AG, Cieplak P, Nam DH, Shiryaev SA, Ge X, Strongin AY. Oncotarget 8 2781-2799 (2017)
  3. Evolutionary convergence and divergence in archaeal chromosomal proteins and Chromo-like domains from bacteria and eukaryotes. Kaur G, Iyer LM, Subramanian S, Aravind L. Sci Rep 8 6196 (2018)
  4. A Small Protein Associated with Fungal Energy Metabolism Affects the Virulence of Cryptococcus neoformans in Mammals. McClelland EE, Ramagopal UA, Rivera J, Cox J, Nakouzi A, Prabu MM, Almo SC, Casadevall A. PLoS Pathog 12 e1005849 (2016)
  5. Inhibition of Marburg Virus RNA Synthesis by a Synthetic Anti-VP35 Antibody. Amatya P, Wagner N, Chen G, Luthra P, Shi L, Borek D, Pavlenco A, Rohrs H, Basler CF, Sidhu SS, Gross ML, Leung DW. ACS Infect Dis 5 1385-1396 (2019)


Reviews citing this publication (9)

  1. Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds. Liu H, Saxena A, Sidhu SS, Wu D. Front Immunol 8 38 (2017)
  2. Synthetic antibody technologies. Adams JJ, Sidhu SS. Curr Opin Struct Biol 24 1-9 (2014)
  3. New concepts and aids to facilitate crystallization. Bukowska MA, Grütter MG. Curr Opin Struct Biol 23 409-416 (2013)
  4. Engineered Autonomous Human Variable Domains. Nilvebrant J, Tessier PM, Sidhu SS. Curr Pharm Des 22 6527-6537 (2016)
  5. Evolution of phage display libraries for therapeutic antibody discovery. Zhang Y. MAbs 15 2213793 (2023)
  6. Synthetic approach to the generation of antibody diversity. Shim H. BMB Rep 48 489-494 (2015)
  7. Potent Neutralization of Staphylococcal Enterotoxin B In Vivo by Antibodies that Block Binding to the T-Cell Receptor. Chen G, Karauzum H, Long H, Carranza D, Holtsberg FW, Howell KA, Abaandou L, Zhang B, Jarvik N, Ye W, Liao GC, Gross ML, Leung DW, Amarasinghe GK, Aman MJ, Sidhu SS. J Mol Biol 431 4354-4367 (2019)
  8. Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives. Henrique IM, Sacerdoti F, Ferreira RL, Henrique C, Amaral MM, Piazza RMF, Luz D. Front Cell Infect Microbiol 12 825856 (2022)
  9. Protein engineering strategies for the development of viral vaccines and immunotherapeutics. Koellhoffer JF, Higgins CD, Lai JR. FEBS Lett 588 298-307 (2014)

Articles citing this publication (89)